Table 1.
Comparison of the sensitivity of anti-NMDAR test between the two detection probes–FITC and Alexa Fluor 488.
| Subject* | Status of anti-NMDAR encephalopathy | Anti-NMDAR titer# | |
|---|---|---|---|
| FITC | Alexa Fluor 488 | ||
| pt 1 | Cured | 1:10 | 1:32 |
| pt 2 | Cured | 1:10 | 1:10 |
| pt 3 | Cured | 1:10 | 1:32 |
| pt 4 | Recurrent | 1:32 | 1:320 |
| pt 5 | Recurrent | 1:32 | 1:100 |
| pt 6 | Cured | Indeterminate | 1:10 |
| Psychiatric day-care patients**(n = 26) | – | – | 25 negative; 1 positive (blood titer 1:32)## |
| Healthy controls (n = 101) | – | – | All negative (101/101) |
*
Patient (pt) subjects diagnosed of anti-NMDAR encephalitis fulfilled the diagnostic criteria listed in Graus et al. (1).
**
These were stable psychiatric patients attending programs at MMH Psychiatric Day-Care Centre: 23/26 schizophrenia; 3/26 bipolar disorder.
#
The anti-NMDAR titer was determined by the highest possible dilution of a patient's plasma or serum sample which could still reveal fluorescence signals from anti-NMDAR autoAb labeling.
##
The only blood anti-NMDAR-positive patient is a stable patient with schizophrenia, whose symptoms do not meet the criteria for possible autoimmune encephalitis (1).